1.Study On Clinical Significance Of SKP2 In Glioma 2.Prognostic Significance Of Preoperative Lymphocyte-monocyte Ratio In Patients With Glioblastoma

Part 1:Study on clinical significance of SKP2 in gliomaObjectives:To investigate the expression of SKP2 in glioma and their correlation with clinicopathological parameters.Methods:395 glioma specimens were collected and an immunohistochemistry was performed to detect the expression of SKP2,p-Rb and EGFR.The associations between SKP2 expression and clinical parameters were analyzed.Kaplan-Meier survival curves were constructed,and the differences were examined by the long-rank test.Results:Positive immunostaining of SKP2 was located in the nuclei of tumor cells However,no SKP2 immunostaining was observed in non-neoplastic tissue.In the tested gliomas,high SKP2 expression was observed mainly in glioblastomas(P<0.001).Also,the expression of SKP2 was associated with p-Rb and EGFR protein expression regardless of tumor grade.However,no correlation was observed between SKP2 expression and TERT promoter mutation.Survival curves showed that the survival time of high SKP2 expression group was shorter than low expression group in glioblastoma(10.04 VS 16.5 months,P=0.0029).Cox analysis further confirmed that SKP2 was independently prognostic factor in glioblastoma.Importantly,a combination of SKP2,IDHIR132H mutation and TERT promoter mutation can classify glioblastoma patients into three subgroups.Patients with low SKP2 expression,IDHIR132H mutation and TERT promoter wild type showed the longest survival time in these three subgroups.Conclusions:SKP2 was highly expressed in glioblastoma and closely related to clinicopathological parameters.Glioblastoma can be further classified into three groups by combining SKP2,IDHIR132H and TERT promoter.Therefore,SKP2 could serve as a potential prognostic biomarker in GBMs.Part 2:Preoperative LMR could serve as prognostic biomarker in patients with glioblastomaObjectives:Preoperative lymphocyte-monocyte ratio(LMR)has been widely demonstrated to predict prognosis in many malignancies.However,the role of LMR in glioma is still unclear.The aim of this study was to investigate the clinical significance of LMR in glioblastoma(GBM).Methods:A retrospective study of 102 GBMs was performed.Peripheral blood samples were collected,and lymphocyte-monocyte ratio(LMR),neutrophil-lymphocyte ratio(NLR),platelet-lymphocyte ratio(PLR),fibrinogen-albumin ratio(FAR)and prognostic nutritional index(PNI)were calculated based on clinical laboratory testing Immunohistochemistry was used to examine the expression of pathological biomarkers,including Ki67,glial fibrillary acidic protein(GFAP),and oligodendrocyte transcription factor 2(Olig2).The associations between LMR and other biomarkers including hematologic and pathological markers were also analyzed.Results:The optimal cutoff value of LMR for survival analysis was 3.2,which result in the most significant difference.Patients with low(<3.2)LMR had significantly shorter survival time than those with high(>3.2)LMR(median overall survival:10.33 VS 18.53 months,P=0.0013).Besides,decreased LMR indicates lower 1-year and 2-year survival rate.Univariate and multivariate analysis further identified that LMR was an independent prognostic factor in GBM.Interestingly,LMR was strongly associated NLR(P<0.001),PLR(P=0.001),and PNI(P<0.001).Furthermore,LMR was negatively correlated with Ki67 expression(P=0.0028),regardless of GFAP(P=0.0864)and Olig2(P=0.4718).Conclusions:Preoperative LMR can predict the prognosis of glioblastoma,and a low LMR indicates poor prognosis.LMR was correlated with NLR,PLR,PNI and tumorous Ki67 expression.Therefore,LMR is a potential prognosis biomarker for glioblastoma.